FINWIRES · TerminalLIVE
FINWIRES

ADP表示,4月私部門招聘增速創下自2025年1月以來的最快水準。

By

-- 美國就業數據公司ADP週三公佈的數據顯示,4月美國私部門就業成長創一年多來新高,官方就業報告將於本週稍晚發布。 薪資處理公司ADP表示,上月私部門新增就業10.9萬個,創下自2025年1月以來的最快成長率。彭博社總結的一項調查顯示,市場普遍預期新增就業12萬個。 ADP數據顯示,3月新增就業人數從6.2萬個下調至6.1萬個。 牛津經濟研究院高級美國經濟學家馬修·馬丁在一份發給的報告中表示:“ADP就業報告顯示私營部門就業人數增長,這不僅表明勞動力市場穩定,而且表明儘管伊朗戰爭爆發,勞動力市場仍有可能回暖。” “如果週五公佈的官方數據也反映出這一信號,鑑於盈虧平衡點信號(我們估計接近零),失業率可能會下降。 根據彭博社總結的一項調查顯示,美國勞工統計局預計將於週五公佈的數據顯示,4月份美國非農業就業人數增加了6.5萬人,低於3月的17.8萬人。失業率預計將維持在4.3%不變。 ADP表示,上個月服務業新增就業9.4萬個,其中教育和醫療服務業增幅最大,達6.1萬人。貿易、運輸和公用事業就業人數反彈,增加了2.5萬人,而專業和商業服務業則減少了8,000人。商品生產業的就業人數增加了1.5萬人。 ADP首席經濟學家內拉·理查森表示:“小型和大型雇主都在招聘,但我們看到中型企業的招聘活動有所疲軟。” “大型企業擁有可部署的資源,而小型企業則最為靈活,這在復雜的勞動力市場環境中都是重要的優勢。” 根據ADP數據顯示,4月大中小型企業共新增就業機會超過10萬個,其中中型企業新增就業人數2,000個。 報告顯示,4月留任者的年薪較上季成長略微放緩至4.4%,而跳槽者的薪資成長則維持穩定,為6.6%。 週二,美國勞工統計局(BLS)報告稱,3月份職缺數量下降,但招聘人數上升。

Price: $207.19, Change: $-3.41, Percent Change: -1.62%

Related Articles

Australia

Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says

Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%

$APTV$F
Research

Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target

Price: $15.79, Change: $-4.34, Percent Change: -21.55%

$CRTO
Australia

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%

$OCUL